title: Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research?
authors: Antonio
authors: A
authors: Passaro
authors: Morena
authors: M
authors: Fasano
authors: Emilio
authors: E
authors: Bria
authors: Floriana
authors: F
authors: Morgillo
authors: Flavia
authors: F
authors: Cantile
authors: Daniele
authors: D
authors: Alesini
authors: Arianna
authors: A
authors: Pellegrino
authors: Enrico
authors: E
authors: Cortesi
authors: Fortunato
authors: F
authors: Ciardiello
mesh_terms: D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D064420:Drug-Related Side Effects and Adverse Reactions; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics
chemical_list: D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride